生物活性 | |||
---|---|---|---|
描述 | Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM[3]. Rabeprazole is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity used in the therapy of gastroesophageal reflux and peptic ulcer disease[4]. Rabeprazole can attenuate the cell viability of human gastric cancer cells through inactivation of the ERK1/2 (extracellular signal-regulated protein kinase 1/2) signaling pathway[5]. Femurs from mice received rabeprazole showed widely separated, thin-walled bone trabeculae and increased number of osteoclasts[6]. In human studies, once-daily doses of 5-40 mg of rabeprazole inhibit gastric acid secretion in a dose-dependent fashion[7]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00234117 | Bronchial Asthma ... 展开 >> Gastroesophageal Reflux 收起 << | Not Applicable | Completed | - | Puerto Rico ... 展开 >> Ponce Gastroentrology Research Ponce, Puerto Rico, 00717 收起 << |
NCT01237353 | Pharmacodynamic | Not Applicable | Completed | - | United States, California ... 展开 >> University of California San Francisco San Francisco, California, United States, 94143 收起 << |
NCT01237353 | - | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.62mL 0.52mL 0.26mL |
13.11mL 2.62mL 1.31mL |
26.22mL 5.24mL 2.62mL |
参考文献 |
---|
[1]Yamasaki Y, et al. Biomed Rep. 2016, 5(1):118-124. |